Movement Alert｜Vaxcyte, Inc. Rises 5.82% in Pre-Market Trading, Shares Stabilize After Recent VAX-31 Phase 3 Readout and Target Price Increase

Market Focus10-15

On October 15, Vaxcyte, Inc. rose 5.82% in Pre-Market Trading, trading at $68.2 per share, with turnover of $58.9 thousand.

The most relevant recent catalyst remains the company’s positive top-line Phase 3 OPUS-1 data for pneumococcal conjugate vaccine candidate VAX-31, followed by an analyst target price increase to $122 from $110 while maintaining a Buy rating.

Background disclosures show VAX-31 met all pre-specified primary endpoints across age groups, with favorable safety and tolerability versus Prevnar 20 and or Capvaxive. The company previously said these adult Phase 3 data are expected to support a planned biologics license application submission in the first half of 2028. The stock had surged sharply after the clinical update, then pulled back in subsequent sessions, suggesting the latest pre-market rise is occurring against the backdrop of that still-dominant catalyst.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment